These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16965728)

  • 1. Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
    Toto RD
    Curr Hypertens Rep; 2006 Oct; 8(5):409-12. PubMed ID: 16965728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
    Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
    JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
    JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure control, drug therapy, and kidney disease.
    Contreras G; Greene T; Agodoa LY; Cheek D; Junco G; Dowie D; Lash J; Lipkowitz M; Miller ER; Ojo A; Sika M; Wilkening B; Toto RD;
    Hypertension; 2005 Jul; 46(1):44-50. PubMed ID: 15897360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
    Lea J; Greene T; Hebert L; Lipkowitz M; Massry S; Middleton J; Rostand SG; Miller E; Smith W; Bakris GL
    Arch Intern Med; 2005 Apr; 165(8):947-53. PubMed ID: 15851648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
    Douglas JG; Agodoa L
    Kidney Int Suppl; 2003 Feb; (83):S74-6. PubMed ID: 12864879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive drugs and renal protection.
    Fukuda M; Usami T; Yoshida A; Kimura G
    JAMA; 2003 Mar; 289(9):1102-3; author reply 1103. PubMed ID: 12622571
    [No Abstract]   [Full Text] [Related]  

  • 8. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
    Sica DA
    J Clin Hypertens (Greenwich); 2003; 5(2):159-67. PubMed ID: 12671332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
    Norris K; Bourgoigne J; Gassman J; Hebert L; Middleton J; Phillips RA; Randall O; Rostand S; Sherer S; Toto RD; Wright JT; Wang X; Greene T; Appel LJ; Lewis J;
    Am J Kidney Dis; 2006 Nov; 48(5):739-51. PubMed ID: 17059993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
    Thornley-Brown D; Wang X; Wright JT; Randall OS; Miller ER; Lash JP; Gassman J; Contreras G; Appel LJ; Agodoa LY; Cheek D
    Arch Intern Med; 2006 Apr; 166(7):797-805. PubMed ID: 16606818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the management of special populations: racial and ethnic populations.
    Ferdinand KC
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):50S-54S. PubMed ID: 14625162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
    Appel LJ; Wright JT; Greene T; Kusek JW; Lewis JB; Wang X; Lipkowitz MS; Norris KC; Bakris GL; Rahman M; Contreras G; Rostand SG; Kopple JD; Gabbai FB; Schulman GI; Gassman JJ; Charleston J; Agodoa LY;
    Arch Intern Med; 2008 Apr; 168(8):832-9. PubMed ID: 18443258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade.
    Basile JN
    J Clin Hypertens (Greenwich); 2001; 3(5):315-6. PubMed ID: 11675775
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal outcomes in hypertensive Black patients at high cardiovascular risk.
    Weir MR; Bakris GL; Weber MA; Dahlof B; Devereux RB; Kjeldsen SE; Pitt B; Wright JT; Kelly RY; Hua TA; Hester RA; Velazquez E; Jamerson KA
    Kidney Int; 2012 Mar; 81(6):568-76. PubMed ID: 22189843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
    Omae K; Ogawa T; Nitta K
    Heart Vessels; 2010 May; 25(3):203-8. PubMed ID: 20512447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?
    McConaghy JR
    J Fam Pract; 2001 Sep; 50(9):744. PubMed ID: 11674903
    [No Abstract]   [Full Text] [Related]  

  • 19. Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.
    Lash JP; Wang X; Greene T; Gadegbeku CA; Hall Y; Jones K; Kusek JW; Sika M; Unruh M;
    Am J Kidney Dis; 2006 Jun; 47(6):956-64. PubMed ID: 16731290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis.
    Flack JM
    Curr Hypertens Rep; 2002 Jun; 4(3):183-4. PubMed ID: 12003698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.